KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Novavax (NVAX) Research & Development: 2009-2025

Historic Research & Development for Novavax (NVAX) over the last 17 years, with Sep 2025 value amounting to $98.3 million.

  • Novavax's Research & Development rose 12.75% to $98.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $370.8 million, marking a year-over-year decrease of 17.87%. This contributed to the annual value of $391.2 million for FY2024, which is 46.96% down from last year.
  • Per Novavax's latest filing, its Research & Development stood at $98.3 million for Q3 2025, which was up 24.03% from $79.2 million recorded in Q2 2025.
  • Novavax's Research & Development's 5-year high stood at $963.0 million during Q4 2021, with a 5-year trough of $79.2 million in Q2 2025.
  • For the 3-year period, Novavax's Research & Development averaged around $126.8 million, with its median value being $104.4 million (2024).
  • Its Research & Development has fluctuated over the past 5 years, first surged by 3,407.97% in 2021, then slumped by 73.22% in 2022.
  • Over the past 5 years, Novavax's Research & Development (Quarterly) stood at $963.0 million in 2021, then tumbled by 73.22% to $257.9 million in 2022, then slumped by 36.13% to $164.7 million in 2023, then tumbled by 36.62% to $104.4 million in 2024, then increased by 12.75% to $98.3 million in 2025.
  • Its Research & Development stands at $98.3 million for Q3 2025, versus $79.2 million for Q2 2025 and $88.9 million for Q1 2025.